Clear Search

Showing 36 results for “B” published 2023.

January 2024

Telitacicept in Patients with Active Systemic Lupus Erythematosus: Results of A Phase 2b, Randomised, Double-blind, Placebo-controlled Trial

Ann Rheum Dis. 2023; DOI: 10.1136/ard-2023-224854

This Phase 2 trial demonstrated the efficacy and acceptable safety profile of telitacicept in patients with SLE. The safety profile of telitacicept was comparable with that observed in clinical trials of other B cell-targeting agents.

more…

Burden of Systemic Lupus Erythematosus in Clinical Practice: Baseline Data from the SLE Prospective Observational Cohort Study (SPOCS) by Interferon Gene Signature

Lupus Sci Med. 2023; 10(2):e001032 DOI: 10.1136/lupus-2023-001032

This study from Arnaud et al described baseline characteristics of SLE patients grouped by disease activity and IFNGS category in the international SPOCS study. IFNGS-high patients were younger at SLE diagnosis, and a baseline SLEDAI-2K score ≥10 was associated with shorter disease duration, more frequent and more severe flares. IFNGS-low patients were more likely to exhibit musculoskeletal and CNS comorbidities than IFNGS-high patients. Continuation of the SPOCS study will allow investigation into how different baseline characteristics affect long-term outcomes in SLE patients.

more…

December 2023

Kidney Outcomes and Preservation of Kidney Function with Obinutuzumab in Patients with Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial

Arthritis Rheumatol. 2023 DOI 10.1002/art.42734

This post hoc analysis of the Phase 2 NOBILITY trial determined that obinutuzumab plus standard of care improved the likelihood of long-term preservation of kidney function and improved kidney function with less glucocorticoid use in patients with lupus nephritis.

more…

Efficacy and Safety of Telitacicept in Patients with Systemic Lupus Erythematosus: A Multicentre, Retrospective, Real-World Study

Lupus Sci. Med. 2023;10(2):e001074 DOI 10.1136/lupus-2023-001074

In this study, telitacicept add-on therapy demonstrated desirable real-world safety and efficacy profiles for the management of SLE, LN, and patients with haematological abnormalities.

more…

November 2023

Emerging Immunotherapeutic Strategies for Cutaneous Lupus Erythematosus: An Overview of Recent Phase 2 and 3 Clinical Trials

Expert Opin Emerg Drugs 2023;28(4):257–73 DOI: 10.1080/14728214.2023.2273536

Current treatments for refractory CLE are insufficient, often leading to suboptimal disease control, and demanding escalated therapies associated with systemic toxicities. However, recent Phase 2 & 3 trials offer promising results, suggesting new therapeutics approved for CLE are on the horizon.

more…

EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update

Ann Rheum Dis 2023;83(1):15–29 DOI: 10.1136/ard-2023-224762

 The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.

more…

October 2023

Repeat Kidney Biopsy Findings of Lupus Nephritis Patients in Clinical Remission Treated with Mycophenolate Associated with Belimumab or Mycophenolate Plus Standard of Care Therapy. A “Post-hoc" Analysis of Participants in the BLISS-LN and Open Label Extension Study Belonging to a Single Center

doi: 10.1177/09612033231204070 Epub ahead of print

Single-centre study concludes that adding belimumab to the standard of care treatment with mycophenolate (MMF) increases the possibility of achieving a complete clinical response (CCR), complete histological response (CHR), and a lower rate of relapses during treatment and long follow-up.

more…

Impact of Low Disease Activity, Remission, and Complete Remission on Flares Following Tapering of Corticosteroids and Immunosuppressive Therapy in Patients with Systemic Lupus Erythematous: A Multinational Cohort Study

The Lancet Rheumatology, 2023, Volume 5, Issue 10, e584 - e593 DOI: https://doi.org/10.1016/S2665-9913(23)00209-6

In this study, tapering of corticosteroids or immunosuppressive therapy in patients in LLDAS, remission, or complete remission was associated with excess flares versus continuing with therapy. Tapering in complete remission was associated with lower odds of flares compared with tapering in LLDAS or remission. In addition, patients with longer sustained duration of LLDAS or remission at the time of tapering had lower odds of flare and longer time to flare versus those with a shorter duration of LLDAS or remission.

more…